🔎 Trials Near Me

Home › Chronic Kidney Disease › NCT05546099

Patient-driven Management of BP in CKD

RecruitingPhase 3

Pharmacist-guided, Patient-driven Management of High Blood Pressure in CKD: A Novel Approach

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Age \>= 18 years,
* CKD stage 3 or 4 (estimated GFR: 15-59 mL/min/1.73m2) or
* Stage 2 CKD (estimated GFR 60-89 mL/min/1.73m2) with urinary albumin/creatinine ratio (ACR 300 mg/g if no DM and 30 mg/g if with DM), and
* Uncontrolled hypertension defined as the avg of 2 readings \> 140 systolic.

Exclusion Criteria:

* Severely uncontrolled hypertension defined as systolic BP \>180,
* Patients with resistant hypertension and taking 4 BP medications,
* Orthostatic hypotension defined as reduced systolic BP by 20 mmHg or diastolic BP by 10 mmHg after 3 minutes of standing,
* Severe CKD defined as estimated GFR \< 20 mL/min/1.73m2,
* Life expectancy \<1 year,
* Severe liver disease,
* Severe congestive heart failure,
* Severe cognitive decline due to dementia,
* Pregnant, breastfeeding, or unwilling to use adequate birth control

About the study

The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study. The study will further evaluate factors that may influence the Veteran to accept the self-management approach and what factors in the VHA healthcare system affect the implementation of the self-management approach.

What is being tested

Sponsor: VA Office of Research and Development · Participants: 160 · Started: Dec 15, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05546099

Locations in the U.S.

IowaIowa City VA Health Care System, Iowa City, IA, Iowa City

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.